Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer

Oncologist

Volumn 19, Issue 5, 2014, Pages 477-482

  Dadu, Ramona ^a,c   Waguespack, Steven G ^a   Sherman, Steven I ^a   Hu, Mimi I ^a   Busaidy, Naifa L ^a   Jimenez, Camilo ^a   Habra, Mohammed A ^a   Ying, Anita K ^a   Bassett, Roland L ^b   Cabanillas, Maria E ^a  

^a Departments of Endocrine Neoplasia and Hormonal Disorders   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Adverse events; Dose reduction; Drug interruptions; Overall survival; Time to failure

Indexed keywords

ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; SORAFENIB;

ANALOGS AND DERIVATIVES; CARCINOMA; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; THYROID NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS;

EID: 84900022883     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0409     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-1214.
3. Tuttle RM, Ball DW, Byrd D et al. Thyroid carcinoma. J Natl Compr Canc Netw 2010;8: 1228-1274.
4. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972.
5. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-1694.
6. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11: 5472-5480.
7. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. The Oncologist 2007;12:426-437.
8. Awada A, Hendlisz A, Gil T et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92: 1855-1861.
9. Kloos RT, Ringel MD, Knopp MV et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-1684.
10. Hoftijzer H, Heemstra KA, Morreau H et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-931.
11. Gupta-Abramson V, Troxel AB, Nellore A et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-4719.
12. Ahmed M, Barbachano Y, Riddell A et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: A phase II study in a UK based population. Eur J Endocrinol 2011;165:315-322.
13. Schneider TC, Abdulrahman RM, Corssmit EP et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial. Eur J Endocrinol 2012;167: 643-650.
14. Brose M, Nutting C, Jarzab Betal. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 2013;39(suppl):4a.
15. Schlumberger M, Jarzab B, Elisei R et al. Phase III randomized, double-blinded, placebo-controlled trial in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) - exploratory analyses of patient-reported outcomes. Abstract 100 presented at: Annual Meeting of the American Thyroid Association; October 16-20, 2013; San Juan, Puerto Rico.
16. Chen L, Shen Y, Luo Q et al. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011; 21:119-124.
17. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
18. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
19. Carhill AA, Cabanillas ME, Jimenez C et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 2013;98:31-42.